Genmab A/S (OTCMKTS:GNMSF) Sees Significant Growth in Short Interest

Genmab A/S (OTCMKTS:GNMSF) saw a significant increase in short interest in September. As of September 15th, there was short interest totalling 91,800 shares, an increase of 37.2% from the August 31st total of 66,900 shares. Based on an average daily trading volume, of 1,200 shares, the short-interest ratio is presently 76.5 days.

Separately, Barclays restated an “overweight” rating on shares of Genmab A/S in a report on Thursday, August 13th.

Shares of OTCMKTS:GNMSF traded down $5.80 during midday trading on Thursday, hitting $367.16. The company’s stock had a trading volume of 92 shares, compared to its average volume of 2,701. The stock has a market capitalization of $22.65 billion, a price-to-earnings ratio of 5.22 and a beta of 0.63. The stock’s 50 day simple moving average is $366.11 and its 200 day simple moving average is $301.97. Genmab A/S has a fifty-two week low of $159.45 and a fifty-two week high of $391.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.53 and a current ratio of 9.53.

Genmab A/S (OTCMKTS:GNMSF) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $65.11 earnings per share (EPS) for the quarter. The company had revenue of $805.11 million for the quarter. Genmab A/S had a return on equity of 38.31% and a net margin of 54.67%.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Further Reading: What is Compound Annual Growth Rate (CAGR)?

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with's FREE daily email newsletter.